United Cannabis Corp (OTCMKTS:CNAB) progress in commencing clinical studies to assess its Prana Bio Medicinals CBD compounds has been in focus recently. More recently, the details were covered by the CFN Media Group and published for readers.
United Cannabis’s Prana Bio Medicinal offering provides patients with a means to mix and match cannabinoids for therapeutic purposes. Applying a patent-pending know-how, the company infuses and flavonoids, cannabinoids and terpenes, without the use of any chemicals, heat or solvents to manufacture 100% natural products.
These offerings interact with the endocannabinoid system, which is responsible for homeostasis. They are divided into five color-coded segments and are available as sublinguals, topicals or capsules. CTO Tony Verzura reported that they pride ourselves on not utilizing any chemical solvents, such as nButane, C02, Hexane and Ethanol, in extraction process.
They use patent-pending infusion procedure that extracts terpenes, phytocannabinoids and flavonoids from raw flower cog without the application of heat. Heat activates compounds and results in the euphoric and hypnotic feeling generally witnessed with THC when combined with certain terpene profiles.
United Cannabis has systematically created numerous raw and active sets, delivery mechanisms, and doses that turns it easy for practitioners, researchers or educated patients to target the Endocannabinoid system. The P1 thru P5 segments systematically categorize chemotypes of cultivars that show different ratios of CBD, THC and terpene profiles. It is the only firm in the world offering both active and raw ingredients in a crop-based hypoallergenic formula with numerous delivery processes ranging from 1 mg to 50 mg doses.
In addition to the products, they offer a complimentary program administered by expert practitioners to assist patients personalize the drugs for their specific requirements. The combination of company’s products being used in the leading market in the U.S. serving thousands of people, and integrated approach to personalized care separates company from the competition.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: